Table 4.
TH | BZB | |||||
---|---|---|---|---|---|---|
TH treatment | TH AE | % of pts with AE | BZB treatment | BZB AE | % of pts with AE | |
male pts | 41 | 25 | 61 | 23 | 6 | 26 |
female pts | 26 | 12 | 46a | 46 | 27 | 59b |
ENG pts | 17 | 17 | 100 | 10 | 2 | 20c |
ACVRL1 pts | 34 | 14 | 41 | 57 | 17 | 30d |
Comparing males to females : ap=0.32, b<0.01. Comparing thalidomide to bevacizumab, cp<0.001, d=0.36